TTI-109 delivered TTI-101-equivalent exposure with improved tolerability and meaningful reductions in disease-relevant STAT3-driven immune cell ...
A new study led by researchers at The University of Texas MD Anderson Cancer Center has identified a way to tailor drug ...
An electronics industry association report projected that the U.S. would surpass 100 million smart wearable users for the ...
A new study led by researchers at The University of Texas MD Anderson Cancer Center has identified a way to tailor drug ...
Levacetylleucine (Aqneursa) improved functioning in a phase III crossover trial of adults and children with ataxia-telangiectasia. Two patients had three treatment-emergent adverse events; none were ...
Morning Overview on MSN
A new pancreatic-cancer drug nearly doubled survival and cut the risk of death by 60%
Patients with previously treated metastatic pancreatic cancer lived nearly twice as long when given daraxonrasib compared ...
HOUSTON, JULY 2, 2026 ― A new study led by researchers at The University of Texas MD Anderson Cancer Center has identified a way to tailor drug ...
InflaRx intends to engage with EMA regarding both vilobelimab and izicopan to evaluate the regulatory path to approval in ANCA-associated ...
Morning Overview on MSN
The FDA approved a lower-dose contrast agent to cut patients’ exposure during MRI scans
Patients who need repeated MRI scans with contrast dye could soon receive a fraction of the gadolinium they currently get.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results